Orchid Pharma Ltd (ORCHPHARMA) Q3FY26 Management Mirror - Dec-2025 Qtr
Financial Outlook & Margins
Reaffirmed (Dec'25 Qtr): Management continues to view FY26 as a "transition year" with muted operational performance.
Modified (Dec'25 Qtr): While maintaining a cautious stance, management noted "green shoots" of recovery in Jan'26 regarding pricing/demand, a shift from the Sep'25 Qtr view which saw "no signs of revival."
Lowered (Sep'25 Qtr): Gross margin expectations were reset. In Jun'25 Qtr, management aimed to maintain ~42%. By Sep'25 Qtr, margins fell to ~32%. In Dec'25 Qtr, margins remained at ~31%, with improvements contingent on a mix shift to regulated markets (target: 40%-65%).
4 more themes on the ELITE plan.